Ziltivekimab associated with multiple proatherogenic inflammatory pathways – secondary analysis of the RESCUE trial
1. In this secondary analysis of the RESCUE trial, targeted interleukin 6 (IL-6) ligand inhibition with ziltivekimab was associated with ...